161 related articles for article (PubMed ID: 37715360)
1. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract][Full Text] [Related]
2. Detailed Chemistry Studies of
Eryilmaz K; Kilbas B
Curr Radiopharm; 2022; 15(1):76-83. PubMed ID: 34053430
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of
Dumond ARS; Rodnick ME; Piert MR; Scott PJH
Curr Radiopharm; 2022; 15(2):96-103. PubMed ID: 34250876
[TBL] [Abstract][Full Text] [Related]
4. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Thiele NA; Wilson JJ
Cancer Biother Radiopharm; 2018 Oct; 33(8):336-348. PubMed ID: 29889562
[TBL] [Abstract][Full Text] [Related]
5. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
6. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
7. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
8. Actinium-225 Targeted Agents: Where Are We Now?
Mourtada F; Tomiyoshi K; Sims-Mourtada J; Mukai-Sasaki Y; Yagihashi T; Namiki Y; Murai T; Yang DJ; Inoue T
Brachytherapy; 2023; 22(6):697-708. PubMed ID: 37690972
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies.
Abou DS; Zerkel P; Robben J; McLaughlin M; Hazlehurst T; Morse D; Wadas TJ; Pandya DN; Oyama R; Gaehle G; Nickels ML; Thorek DLJ
Cancer Biother Radiopharm; 2022 Jun; 37(5):355-363. PubMed ID: 35695807
[No Abstract] [Full Text] [Related]
11. Evolving role of
Satapathy S; Sood A; Das CK; Mittal BR
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
[TBL] [Abstract][Full Text] [Related]
12.
Rubira L; Deshayes E; Santoro L; Kotzki PO; Fersing C
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111537
[TBL] [Abstract][Full Text] [Related]
13. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Thiele NA; Brown V; Kelly JM; Amor-Coarasa A; Jermilova U; MacMillan SN; Nikolopoulou A; Ponnala S; Ramogida CF; Robertson AKH; Rodríguez-Rodríguez C; Schaffer P; Williams C; Babich JW; Radchenko V; Wilson JJ
Angew Chem Int Ed Engl; 2017 Nov; 56(46):14712-14717. PubMed ID: 28963750
[TBL] [Abstract][Full Text] [Related]
14. Calcium Carbonate Core-Shell Particles for Incorporation of
Muslimov AR; Antuganov DO; Tarakanchikova YV; Zhukov MV; Nadporojskii MA; Zyuzin MV; Timin AS
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25599-25610. PubMed ID: 34028266
[TBL] [Abstract][Full Text] [Related]
15. A suitable time point for quantifying the radiochemical purity of
Kelly JM; Amor-Coarasa A; Sweeney E; Wilson JJ; Causey PW; Babich JW
EJNMMI Radiopharm Chem; 2021 Dec; 6(1):38. PubMed ID: 34928478
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
[TBL] [Abstract][Full Text] [Related]
17. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
18. Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A; Apostolidis C; Bruchertseifer F
Semin Nucl Med; 2020 Mar; 50(2):119-123. PubMed ID: 32172796
[TBL] [Abstract][Full Text] [Related]
19. H
Kadassery KJ; King AP; Fayn S; Baidoo KE; MacMillan SN; Escorcia FE; Wilson JJ
Bioconjug Chem; 2022 Jun; 33(6):1222-1231. PubMed ID: 35670495
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Kaneda-Nakashima K; Shirakami Y; Kadonaga Y; Watabe T; Ooe K; Yin X; Haba H; Shirasaki K; Kikunaga H; Tsukada K; Toyoshima A; Cardinale J; Giesel FL; Fukase K
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
